Olinvacimab is a reference antibody targeting VEGFR2 (KDR/CD309), a key receptor involved in angiogenesis—the formation of new blood vessels. Its primary application lies in cancer research and therapeutic development, particularly in inhibiting tumor growth by blocking vascular endothelial growth factor (VEGF)-mediated signaling. By binding to VEGFR2, olinvacimab prevents VEGF from activating the receptor, thereby suppressing endothelial cell proliferation, migration, and survival, which are critical for tumor angiogenesis. It is widely used as a benchmark in the development and validation of biosimilars and anti-angiogenic drugs. Researchers utilize olinvacimab in immunoassays, neutralization studies, and pharmacokinetic comparisons to evaluate the efficacy and binding characteristics of novel therapeutic antibodies. Additionally, it serves as a critical tool in preclinical studies to understand angiogenesis pathways and assess the potential of combination therapies involving immune checkpoint inhibitors or chemotherapy agents. Due to its well-characterized specificity and function, olinvacimab supports quality control in biopharmaceutical manufacturing and aids in standardizing assays for drug development in oncology.